Monoclonal Antibody to ATPase, Na+/K+ Transporting Alpha 1 Polypeptide (ATP1a1)
Code | Size | Price |
---|
MAG369Hu23-20ul | 20uL | £99.00 |
Quantity:
MAG369Hu23-100ul | 100ul | £189.00 |
Quantity:
MAG369Hu23-200ul | 200ul | £257.00 |
Quantity:
MAG369Hu23-1ml | 1ml | £597.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2b Kappa
Antibody Clonality: Monoclonal
Antibody Clone: C210
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
Sodium pump subunit alpha-1; Na(+)/K(+) ATPase alpha-1 subunit; Sodium/potassium-transporting ATPase subunit alpha-1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
ATPase, Na+/K+ Transporting Alpha 1 Polypeptide
Potency (Clone Number):
C210
Reactivity:
Mu;Ra;Rb;Po;Bo;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant ATPase, Na+/K+ Transporting Alpha 1 Polypeptide (ATP1a1) | RPG369Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||